Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

Mogens Groenvold, Peter Fayers, Morten Aagard Petersen, Mirjam A. G. Sprangers, Neil K. Aaronson, Henning T. Mouridsen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals' knowledge of HRQL.

Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to 'low-risk' patients not on chemotherapy ('control group'). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.

After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.

This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.

Original languageEnglish
Pages (from-to)185-195
Number of pages11
JournalBreast Cancer Research and Treatment
Volume103
Issue number2
Early online date13 Oct 2006
DOIs
Publication statusPublished - Jun 2007

Keywords

  • breast neoplasms
  • adjuvant therapy
  • chemotherapy
  • outcomes
  • quality of life
  • quality-of-life
  • randomized-trial
  • questionnaire QLQ-C30
  • European-organization
  • adjusted survival
  • clinical-trials
  • therapy
  • women
  • validation
  • impact

Cite this

Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. / Groenvold, Mogens; Fayers, Peter; Petersen, Morten Aagard; Sprangers, Mirjam A. G.; Aaronson, Neil K.; Mouridsen, Henning T.

In: Breast Cancer Research and Treatment, Vol. 103, No. 2, 06.2007, p. 185-195.

Research output: Contribution to journalArticle

Groenvold, Mogens ; Fayers, Peter ; Petersen, Morten Aagard ; Sprangers, Mirjam A. G. ; Aaronson, Neil K. ; Mouridsen, Henning T. / Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. In: Breast Cancer Research and Treatment. 2007 ; Vol. 103, No. 2. pp. 185-195.
@article{983f7ee629d34cf69acbd1ba3ee4c396,
title = "Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff",
abstract = "Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals' knowledge of HRQL.Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to 'low-risk' patients not on chemotherapy ('control group'). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.",
keywords = "breast neoplasms, adjuvant therapy, chemotherapy, outcomes, quality of life, quality-of-life, randomized-trial, questionnaire QLQ-C30, European-organization, adjusted survival, clinical-trials, therapy, women, validation, impact",
author = "Mogens Groenvold and Peter Fayers and Petersen, {Morten Aagard} and Sprangers, {Mirjam A. G.} and Aaronson, {Neil K.} and Mouridsen, {Henning T.}",
note = "Acknowledgement Supported by the Danish Cancer Society (91-505 and 94 15001).",
year = "2007",
month = "6",
doi = "10.1007/s10549-006-9365-y",
language = "English",
volume = "103",
pages = "185--195",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

AU - Groenvold, Mogens

AU - Fayers, Peter

AU - Petersen, Morten Aagard

AU - Sprangers, Mirjam A. G.

AU - Aaronson, Neil K.

AU - Mouridsen, Henning T.

N1 - Acknowledgement Supported by the Danish Cancer Society (91-505 and 94 15001).

PY - 2007/6

Y1 - 2007/6

N2 - Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals' knowledge of HRQL.Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to 'low-risk' patients not on chemotherapy ('control group'). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.

AB - Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals' knowledge of HRQL.Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to 'low-risk' patients not on chemotherapy ('control group'). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.

KW - breast neoplasms

KW - adjuvant therapy

KW - chemotherapy

KW - outcomes

KW - quality of life

KW - quality-of-life

KW - randomized-trial

KW - questionnaire QLQ-C30

KW - European-organization

KW - adjusted survival

KW - clinical-trials

KW - therapy

KW - women

KW - validation

KW - impact

U2 - 10.1007/s10549-006-9365-y

DO - 10.1007/s10549-006-9365-y

M3 - Article

VL - 103

SP - 185

EP - 195

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -